Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer

Table 3

Comparison of adverse reactions between the two groups of patients.

Adverse reactions	Treatment group (n = 62)		Control group (n = 64)		χ^2
	1-2	3-4	1-2	3-4
Hypertension	5	1	4	0	0.506	0.477
Weakness	12	1	6	10	0.289	0.591
Nausea/vomiting	9	3	8	6	0.122	0.727
Proteinuria	4	5	6	2	0.109	0.741
Neutropenia	1	3	2	0	0.768	0.381
Thrombocytopenia	2	6	5	1	0.397	0.529
Anemia	8	2	6	8	0.674	0.412
Peripheral neurotoxicity	25	5	22	4	0.768	0.381